Compare Incyte Corporation (INCY) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Quanta Services Inc — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while Quanta Services Inc trades at $637.96 (market cap $94.92B). The key difference: Quanta Services Inc is far larger — about 4.1× Incyte Corporation's market cap, and Quanta Services Inc pays a 0.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PWR | |
|---|---|---|
Market Cap | $23.11B | $94.92B |
Sector | Health | Industrials |
52-Week High | $118.52 | $785.24 |
52-Week Low | $67.38 | $372.50 |
Enterprise Value | $19.13B | $100.88B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
PWR trades at $633.04, up 0.72% today, with strong analyst support (27 Buy, 0 Sell) and a consensus price target of $836.80. Recent quarters show consistent EPS beats, with Q1 2026 actual of $2.68 exceeding the $2.04 estimate. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 3.67%. Technical indicators are mixed, with a bearish overall signal but bullish oscillators like RSI near oversold levels.
The outlook is positive due to infrastructure demand from AI and grid modernization, with a projected $2.4T addressable market by 2030. Risks include high valuation multiples (P/E 86.22) and aggressive capital spending impacting cash flow. Institutional sentiment is bullish, but execution risks and economic cycles could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
